Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company specializing in fluid overload solutions, has announced its plans to release second quarter 2024 financial results on August 13, 2024. The company will host a conference call and webcast at 9:00 AM ET to discuss the results and provide a general business update.
Investors and interested parties can access the live webcast through the Investors page on the Nuwellis website. Alternatively, they can join the conference call by dialing 1-800-267-6316 (U.S) or 1-203-518-9783 (international) using the conference ID: NUWEQ2. An audio archive of the webcast will be available on the company's Investors page following the call.
Nuwellis, Inc. (Nasdaq: NUWE), un'azienda di tecnologia medica specializzata in soluzioni per il sovraccarico di fluidi, ha annunciato i suoi piani per pubblicare i risultati finanziari del secondo trimestre 2024 il 13 agosto 2024. L'azienda organizzerà una teleconferenza e una trasmissione via web alle 9:00 AM ET per discutere i risultati e fornire un aggiornamento generale sull'attività.
Gli investitori e le parti interessate possono accedere alla trasmissione in diretta tramite la pagina Investitori sul sito web di Nuwellis. In alternativa, possono partecipare alla teleconferenza componendo il numero 1-800-267-6316 (USA) o 1-203-518-9783 (internazionale) utilizzando l'ID conferenza: NUWEQ2. Un archivio audio della trasmissione sarà disponibile sulla pagina Investitori dell'azienda dopo la chiamata.
Nuwellis, Inc. (Nasdaq: NUWE), una empresa de tecnología médica especializada en soluciones para la sobrecarga de fluidos, ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 el 13 de agosto de 2024. La empresa organizará una llamada de conferencia y una transmisión web a las 9:00 AM ET para discutir los resultados y proporcionar una actualización general del negocio.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la página de Inversores en el sitio web de Nuwellis. Alternativamente, pueden unirse a la llamada de conferencia marcando el 1-800-267-6316 (EE. UU.) o 1-203-518-9783 (internacional) utilizando el ID de conferencia: NUWEQ2. Un archivo de audio de la transmisión estará disponible en la página de Inversores de la empresa después de la llamada.
Nuwellis, Inc. (Nasdaq: NUWE), 체액 과부하 솔루션을 전문으로 하는 의료 기술 회사가 2024년 2분기 재무 결과를 2024년 8월 13일에 발표할 계획이라고 밝혔습니다. 이 회사는 결과에 대해 논의하고 일반적인 비즈니스 업데이트를 제공하기 위해 오전 9:00 ET에 컨퍼런스 콜과 웹캐스트를 진행할 것입니다.
투자자와 이해 관계자는 Nuwellis 웹사이트의 투자자 페이지를 통해 라이브 웹캐스트에 접근할 수 있습니다. 또는 1-800-267-6316 (미국) 또는 1-203-518-9783 (국제전화)로 전화를 걸어 회의 ID: NUWEQ2를 사용해 컨퍼런스 콜에 참여할 수 있습니다. 통화 후 웹캐스트의 오디오 아카이브는 회사의 투자자 페이지에서 제공됩니다.
Nuwellis, Inc. (Nasdaq: NUWE), une entreprise de technologie médicale spécialisée dans les solutions de surcharge liquidienne, a annoncé ses projets de publier les résultats financiers du deuxième trimestre 2024 le 13 août 2024. L'entreprise organisera une conférence téléphonique et un webcast à 9h00 ET pour discuter des résultats et donner une mise à jour générale sur les activités.
Les investisseurs et les parties intéressées peuvent accéder au webcast en direct via la page Investisseurs du site web de Nuwellis. Alternativement, ils peuvent rejoindre la conférence téléphonique en composant le 1-800-267-6316 (États-Unis) ou le 1-203-518-9783 (international) en utilisant l'ID de la conférence : NUWEQ2. Un enregistrement audio du webcast sera disponible sur la page Investisseurs de l'entreprise après l'appel.
Nuwellis, Inc. (Nasdaq: NUWE), ein Medizintechnikunternehmen, das auf Lösungen zur Flüssigkeitsüberlastung spezialisiert ist, hat seine Pläne bekannt gegeben, die Finanzergebnisse für das zweite Quartal 2024 am 13. August 2024 zu veröffentlichen. Das Unternehmen wird eine Telefonkonferenz und ein Webcast um 9:00 AM ET veranstalten, um die Ergebnisse zu besprechen und ein allgemeines Geschäftupdate zu geben.
Investoren und interessierte Parteien können über die Investorenseite auf der Nuwellis-Website auf das Live-Webcast zugreifen. Alternativ können sie an der Telefonkonferenz teilnehmen, indem sie 1-800-267-6316 (USA) oder 1-203-518-9783 (international) wählen und die Konferenz-ID: NUWEQ2 verwenden. Ein Audioarchiv des Webcasts wird nach dem Anruf auf der Investorenseite des Unternehmens verfügbar sein.
- None.
- None.
MINNEAPOLIS, July 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the second quarter of 2024 on Tuesday, August 13, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-267-6316 (U.S) or 1-203-518-9783 (international) and using the conference ID: NUWEQ2. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit ir.nuwellis.com or visit us on LinkedIn or X.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
CONTACTS
INVESTORS:
Vivian Cervantes
Gilmartin Group LLC
ir@nuwellis.com
FAQ
When will Nuwellis (NUWE) release its Q2 2024 financial results?
What time is the Nuwellis (NUWE) Q2 2024 earnings call scheduled for?
How can I access the Nuwellis (NUWE) Q2 2024 earnings webcast?
What are the dial-in numbers for Nuwellis (NUWE) Q2 2024 earnings call?
